Major site upgrade Stevanato Group expands drug delivery manufacturing with new injection molding facility

Source: Stevanato Group 1 min Reading Time

Related Vendors

Stevanato Group is expanding its European manufacturing footprint with a major investment in its Bad Oeynhausen facility, adding more than 2,500 square meters of state-of-the-art production space. Equipped for precision injection moulding and automated assembly, the upgraded site enhances capacity for the company’s autoinjector and pen injector platforms.

Stevanato Group team members at the Bad Oeynhausen site in northern Germany are pictured during the inauguration of the new cleanroom. At the center are Franco Stevanato, CEO; Marco Dal Lago, CFO; and Michele Monico, President of DDS and IVD Business Unit.(Source:  Sona Media/ Businesswire)
Stevanato Group team members at the Bad Oeynhausen site in northern Germany are pictured during the inauguration of the new cleanroom. At the center are Franco Stevanato, CEO; Marco Dal Lago, CFO; and Michele Monico, President of DDS and IVD Business Unit.
(Source: Sona Media/ Businesswire)

As part of its footprint optimization plan, Stevanato Group recently added a state-of-the-art production space for drug delivery devices to its facility in Bad Oeynhausen, northern Germany. This initiative provides more than 2,500 square meters of advanced manufacturing capacity designed to serve global pharma and biotech partners seeking robust and resilient European supply-chain integration.

The multi-million investment includes installation of an ISO 8 cleanroom environment, fully equipped for injection molding and automated assembly operations. These upgrades enable the site to support both Stevanato Group’s proprietary device production and contract manufacturing services enhancing operational flexibility, scalability, and speed-to-market across the company’s drug delivery systems portfolio.

The enhanced Bad Oeynhausen facility plays a pivotal role in advancing the production of key portfolio devices, including the Aidaptus autoinjector and Alina pen injector platforms. By integrating the Company's core capabilities in glass primary packaging, analytical services, and equipment manufacturing, Stevanato Group continues to reinforce its position as a trusted partner in enabling safe, effective, and patient-centric combination products tailored to individual customer requirements.

“This investment underscores our commitment to advancing self-injection technologies and supporting our customers in delivering better patient outcomes,” said Michele Monico, President of DDS and IVD Business Unit at Stevanato Group. “As demand for drug delivery devices accelerates and patient adoption continues to rise — driven by the need for more convenient, personalized treatment options — expanding our manufacturing capacity is a strategic step to ensure readiness, agility, and innovation across our value chain.”.

(ID:50604395)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent